{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T08:44:28Z","timestamp":1792399468813,"version":"4.4.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ijcard.2025.134046","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T07:41:50Z","timestamp":1764056510000},"page":"134046","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Eligibility for Icosapent ethyl in patients undergoing cardiac rehabilitation: A real-world cohort study"],"prefix":"10.1016","volume":"445","author":[{"given":"Filippo","family":"Brucato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Tognola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Moreo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Bellomare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni Pio","family":"Prencipe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Lettino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Trocino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viola","family":"Dadone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Pierini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Viola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Oliva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piera","family":"Merlini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Giannattasio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Maloberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2025.134046_bb0005","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.982815","article-title":"Increased residual cardiovascular risk in U.S. veterans with moderately-elevated baseline triglycerides and well-controlled LDL-C levels on statins","volume":"9","author":"Leatherman","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"issue":"1","key":"10.1016\/j.ijcard.2025.134046_bb0010","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"ESC scientific document group. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2025.134046_bb0015","doi-asserted-by":"crossref","first-page":"133608","DOI":"10.1016\/j.ijcard.2025.133608","article-title":"Prevalence of hypertriglyceridemia and its association with extreme cardiovascular risk in patients with acute and chronic coronary syndrome enrolled in a cardiac rehabilitation program","author":"Tognola","year":"2025","journal-title":"Int. J. Cardiol."},{"issue":"10349","key":"10.1016\/j.ijcard.2025.134046_bb0020","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0140-6736(22)00916-3","volume":"400","author":"Kim","year":"2022","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ijcard.2025.134046_bb0025","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","article-title":"Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology","volume":"118","author":"Nordestgaard","year":"2016","journal-title":"Circ. Res."},{"issue":"9","key":"10.1016\/j.ijcard.2025.134046_bb0030","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.mayocp.2019.03.028","article-title":"Association of elevated triglycerides with increased cardiovascular risk and direct costs in statin-treated patients","volume":"94","author":"Toth","year":"2019","journal-title":"Mayo Clin. Proc."},{"issue":"1","key":"10.1016\/j.ijcard.2025.134046_bb0035","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"REDUCE-IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"34","key":"10.1016\/j.ijcard.2025.134046_bb0040","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"ESC scientific document group. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur. Heart J."},{"issue":"18","key":"10.1016\/j.ijcard.2025.134046_bb0045","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2018.08.1038","volume":"72","author":"Thygesen","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"issue":"36","key":"10.1016\/j.ijcard.2025.134046_bb0050","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur. Heart J."},{"issue":"3","key":"10.1016\/j.ijcard.2025.134046_bb0055","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s40292-021-00444-y","article-title":"Low awareness of cardiovascular risk factor among patients admitted in cardiac rehabilitation unit","volume":"28","author":"Conte","year":"2021","journal-title":"High Blood Press. Cardiovasc. Prev."},{"issue":"8","key":"10.1016\/j.ijcard.2025.134046_bb0060","first-page":"613","article-title":"Livelli di trigliceridi nei pazienti in prevenzione secondaria nel mondo reale: approfondimenti dal registro JET-LDL [Real-world triglyceride levels in secondary prevention: insights from the JET-LDL registry]","volume":"26","author":"Sparasci","year":"2025","journal-title":"G Ital. Cardiol. (Rome)"},{"key":"10.1016\/j.ijcard.2025.134046_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2025.04.193","article-title":"Estimate and prognosis of patients who are candidates for treatment with eicosapentaenoic acid after an acute coronary syndrome","author":"Cordero","year":"2025","journal-title":"J. Clin. Lipidol."},{"issue":"11","key":"10.1016\/j.ijcard.2025.134046_bb0070","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1002\/clc.23437","article-title":"Applicability of the REDUCE-IT trial to the FAST-MI registry. Are the results of randomized trials relevant in routine clinical practice?","volume":"43","author":"Ferri\u00e8res","year":"2020","journal-title":"Clin. Cardiol."},{"issue":"2","key":"10.1016\/j.ijcard.2025.134046_bb0075","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.medj.2022.12.008","article-title":"Generalizability of the REDUCE-IT trial to South Asians with cardiovascular disease","volume":"4","author":"Krishnaraj","year":"2023","journal-title":"Med"},{"issue":"10","key":"10.1016\/j.ijcard.2025.134046_bb0080","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1161\/CIRCULATIONAHA.118.038691","article-title":"Eligibility and cost for icosapent ethyl based on the REDUCE-IT trial: insight from the veterans affairs healthcare system","volume":"139","author":"Jia","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2025.134046_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2022.100345","article-title":"The potential population health impact of treating REDUCE-IT eligible US adults with icosapent ethyl","volume":"10","author":"Derington","year":"2022","journal-title":"Am. J. Prev. Cardiol."},{"key":"10.1016\/j.ijcard.2025.134046_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.athplu.2024.09.002","article-title":"Eligibility for marine omega-3 fatty acid supplementation after acute coronary syndromes","volume":"58","author":"Follonier","year":"2024","journal-title":"Atheroscler Plus."},{"issue":"6","key":"10.1016\/j.ijcard.2025.134046_bb0095","first-page":"1901","article-title":"Eligibility for icosapent ethyl in a French population of coronary outpatients with type 2 diabetes","volume":"19","author":"Sabouret","year":"2023","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.ijcard.2025.134046_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2023.100510","article-title":"Generalizability of REDUCE-IT eligibility criteria in a large diabetes cardiovascular outcomes trial: a post hoc subgroup analysis of EMPA-REG OUTCOME","volume":"15","author":"Verma","year":"2023","journal-title":"Am. J. Prev. Cardiol."},{"issue":"5","key":"10.1016\/j.ijcard.2025.134046_bb0105","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/dom.14965","article-title":"Potential for residual cardiovascular risk reduction: eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease","volume":"25","author":"Kim","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.ijcard.2025.134046_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2022.100345","article-title":"The potential population health impact of treating REDUCE-IT eligible US adults with Icosapent ethyl","volume":"10","author":"Derington","year":"2022","journal-title":"Am. J. Prev. Cardiol."},{"issue":"40","key":"10.1016\/j.ijcard.2025.134046_bb0115","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehaa652","article-title":"Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial","volume":"41","author":"Budoff","year":"2020","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.ijcard.2025.134046_bb0120","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1093\/cvr\/cvaa184","article-title":"Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: a prospective, placebo-controlled randomized trial (EVAPORATE): interim results","volume":"117","author":"Budoff","year":"2021","journal-title":"Cardiovasc. Res."},{"issue":"8","key":"10.1016\/j.ijcard.2025.134046_bb0125","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1080\/14779072.2022.2103541","article-title":"Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements","volume":"20","author":"Miller","year":"2022","journal-title":"Expert. Rev. Cardiovasc. Ther."},{"issue":"3","key":"10.1016\/j.ijcard.2025.134046_bb0130","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.030319","article-title":"Prognostic value and relative cutoffs of triglycerides predicting cardiovascular outcome in a large regional-based Italian database","volume":"13","author":"Tikhonoff","year":"2024","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ijcard.2025.134046_bb0135","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ijcard.2016.11.105","article-title":"Early initiation of eicosapentaenoic acid and statin treatment is associated with better clinical outcomes than statin alone in patients with acute coronary syndromes: 1-year outcomes of a randomized controlled study","volume":"228","author":"Nosaka","year":"2017","journal-title":"Int. J. Cardiol."},{"issue":"1","key":"10.1016\/j.ijcard.2025.134046_bb0140","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/eurheartj\/ehz767","article-title":"Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies","volume":"41","author":"Lawler","year":"2020","journal-title":"Eur. Heart J."},{"issue":"Suppl. 4","key":"10.1016\/j.ijcard.2025.134046_bb0145","first-page":"A34","article-title":"Residual risk in cardiac rehab: can we reduce-it more? Eligibility for icosapent ethyl in patients attending cardiac rehabilitation","volume":"106","author":"Millar","year":"2020","journal-title":"Heart"},{"issue":"9","key":"10.1016\/j.ijcard.2025.134046_bb0150","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the Management of Patients with Chronic Coronary Disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on clinical practice guidelines","volume":"148","author":"Virani","year":"2023","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ijcard.2025.134046_bb0155","first-page":"143","article-title":"The management of acute myocardial infarction in the cardiological intensive care units in Italy: the \u2018BLITZ 4 Qualit\u00e0\u2019 campaign for performance measurement and quality improvement","volume":"1","author":"Olivari","year":"2012","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"issue":"2","key":"10.1016\/j.ijcard.2025.134046_bb0160","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.numecd.2024.08.006","article-title":"Secondary prevention and extreme cardiovascular risk evaluation (SEVERE-0): prevalence of extreme cardiovascular risk in cardiological rehabilitation patients and its impact on functional improvement","volume":"35","author":"Tognola","year":"2025","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"issue":"3","key":"10.1016\/j.ijcard.2025.134046_bb0165","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/JCN.0000000000000332","article-title":"Cardiac rehabilitation: Unraveling the complexity of referral and current models of delivery","volume":"32","author":"Astley","year":"2017","journal-title":"J. Cardiovasc. Nurs."},{"issue":"25","key":"10.1016\/j.ijcard.2025.134046_bb0170","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1093\/eurheartj\/ehw152","volume":"37","author":"Nordestgaard","year":"2016","journal-title":"Eur. Heart J."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527325010897?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527325010897?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T08:15:19Z","timestamp":1792397719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527325010897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":34,"alternative-id":["S0167527325010897"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2025.134046","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eligibility for Icosapent ethyl in patients undergoing cardiac rehabilitation: A real-world cohort study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2025.134046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"134046"}}